Kingo Investment Partners
VC Fund
Seoul, South Korea
Kingo Investment Partners is a venture capital firm.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 7%
Last updated:
For AI agents: llms.txt
Industries Kingo Investment Partners invests in
Stages Kingo Investment Partners invests in
Countries Kingo Investment Partners invests in
Round sizes
Round size
- Series A
- $2.7M–$9.4M
- Series B
- $11M–$20M
- Series C
- $3.2M–$45M
Investment Focus
Industry
- Health Care 8 (30%)
- Biotechnology 8 (30%)
- Therapeutics 5 (19%)
- E-Commerce 4 (15%)
- SaaS 3 (11%)
Stage
- Series A 10 (37%)
- Series C 7 (26%)
- Series B 5 (19%)
- Seed 3 (11%)
- Funding Round 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
IMBiologics
|
IMBiologics is a biotechnology company that develops antibody-based drug candidates for diseases such as cancer and immune-related conditions. It conducts research and development using its own platforms to discover new therapeutic molecules. | $29.5M / Series C / Oct 14, 2025 | |
Colosseum
|
Colosseum is a logistics company that provides e-commerce logistics services to various locations. | $19.6M / Series B / Jun 18, 2025 | |
PEOPLE & TECHNOLOGY
|
PEOPLE AND TECHNOLOGY provides DX-based AI solutions on INDOOR GEOLOCATION AND SMART SENSING through its INDOORPLUS+ IoT, Location Based System (LBS) and Real Time Location System (RTLS) platform in the fields of healthcare, manufacturing, defense, smart cities, and the public sector.More than 100 corporate customers in various business sectorssuch as healthcare, banking, manufacturing, retail, energy and public services have already chosen PEOPLE AND TECHNOLOGY to deploy industry grade solutions for employee safety, asset tracking & monitoring, security & access control, flow management and process efficiency. They have gained improvements in productivity and process efficiency while reducing their corporate risks and optimizing their procurement. Since its foundation in 2013, PEOPLE AND TECHNOLOGY has become a leading provider in South Korea and is expanding overseas. | $5.1M / Series C / May 21, 2025 | |
Polaris3D
|
Polaris3d offers indoor autonomous navigating solution. | $10.9M / Series B / Jun 03, 2024 | |
GPCR Therapeutics
|
GPCR Therapeutics is a clinical-stage international biopharmaceutical firm that develops therapeutics based on proprietary GPCR data. The company was founded in 2013 and is headquartered in Seoul, South Korea. The company’s proprietary data driven approach has identified over 1000 GPCR pairs upon which drug screening campaigns can be pursued.Identification of the best GPCR pair to target for specific disease indications and patient subpopulations creates a personalized approach to combination therapy. By targeting the unique pharmacology of GPCR pairs, we aim to develop life changing treatments for cancer and other diseases. | $3.2M / Series C / Nov 29, 2023 | |
MEZOO
|
MEZOO is a medical device manufacturing company. | $13.8M / Series B / Nov 07, 2023 | |
Medinno
|
Medinno develops cell therapeutics for brain diseases. The company's therapy uses technology to treat a wide range of diseases, including hypoxic-ischemic encephalopathy, neonatal refractory brain diseases, and severe intraventricular hemorrhages.. | $8.2M / Series C / Oct 16, 2023 | |
Difon
|
Difon is a developer of smart window solution technology, which is designed to regulate sunlight transmittance.Difon Co., Ltd. emerged as a spin-off from Hyundai Motor Group in 2021, with a vision to evolve into a leading provider of smart film solutions. The company is dedicated to enhancing consumers' living spaces by conducting researchand development while manufacturing smart films.To accelerate the adoption of smart film technology, Difon has established a robust supply chain through strategic alliances and investments in system integration with various relevant companies, including glass manufacturers, automobile OEMs, and construction firms.With a strong commitment to sustainability and social responsibility, Difon aims to foster a better environment and future through its endeavors. The company strives to maximize its impact by continually innovating and creating products that benefit both consumers and society as a whole. | $9.4M / Series A / Sep 12, 2023 | |
|
IMBiologics
|
IMBiologics is a biotechnology company that develops antibody-based drug candidates for diseases such as cancer and immune-related conditions. It conducts research and development using its own platforms to discover new therapeutic molecules. | $15.6M / Series B / Jul 24, 2023 | |
Ecube Labs
|
Ecube Labs is a provider of smart waste management and logistics solutions that utilize IoT technologies. Our integrated line of products include solar-powered waste compacting bins (CleanCUBE), fill-level sensors (CleanFLEX) that can be fitted to any type of container, and a predictive analytics SaaS platform (Clean City Networks, CCN).Ecubehelps cities and waste collection organizations reduce operational costs by eliminating unnecessary pick-ups and providing dynamic collection routes and schedules for a complete optimization of the collection operations. Our solutions provide actionable insights for decision-makers and operators. | $11.6M / Series C / Jun 20, 2023 | |
| See all 27 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Kingo Investment Partners invest in?
Kingo Investment Partners invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series A and Series C stage. Most of the 27 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Kingo Investment Partners's check size?
Kingo Investment Partners typically joins rounds of $2.7M–$9.4M at Series A, $11M–$20M at Series B and $3.2M–$45M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Kingo Investment Partners participates in.
When did Kingo Investment Partners last invest?
The most recent investment recorded for Kingo Investment Partners closed in Oct 2025. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
